Skip to main navigation Skip to search Skip to main content

The effect of switching patients from risedronate to alendronate on the risk of upper gastrointestinal (GI) adverse events after the introduction of generic alendronate products in the UK

Research output: Contribution to journalMeeting abstractpeer-review

Original languageEnglish
Pages (from-to)S446-S446
Number of pages1
JournalBone
Volume44
Issue number2
DOIs
Publication statusPublished - Jun 2009

Cite this